AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00602355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mothercrafting
Description: Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care
Study NCT00649103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril Hydrochloride Tablets 40 mg
Description: 40mg, single dose fasting
Study NCT00649103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Accupril® Tablets 40 mg
Description: 40mg, single dose fasting
Study NCT04219228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ophthalmic examinations
Description: Ophthalmic examinations include visual acuity, cover test and ocular dominance, noncycloplegic autorefraction, cycloplegia, ocular biometric measurements, cycloplegic auto-refraction, subjective refraction, and anterior and posterior segment examination.
Study NCT04219228 — intervention group
Intervention type: DEVICE
Intervention: Wearable devices
Description: Physical activity, light intensity, and visual information will be measured with wearable devices.
Study NCT03860948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib Test Preparation
Description: Test preparation (T): dry granulation savolitinib tablets.
Study NCT03860948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib Reference Preparation
Description: Reference preparation (R): wet granulation savolitinib tablets.
Study NCT03439033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/MRI with Gallium-68 labeled PSMA-HBED-CC
Description: Subjects have one visit, during which they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
Study NCT03439033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC
Description: Subjects have two visits (the second visit being optional) within two years. During each visit, they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
Study NCT03439033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT with Gallium-68 labeled PSMA-HBED-CC
Description: Subjects have one visit, during which they will undergo one PET/CT with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
Study NCT01560273 — intervention group
Intervention type: DEVICE
Intervention: Aspen Spinous Process Fixation Device
Description: The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
Study NCT04611022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Educational Intervention
Description: The videos are 8-minute narrative films created using an entertainment-education (E-E) approach that embeds an educational narrative message into an entertainment format such as media. E-E narratives have demonstrated a significant effect (r = .12, p \< .001) on health behavior change. Evidence-based small media interventions that Dr. Borrayo has produced include videos that are highly verbal, visual, and entertaining (e.g., acted fictional stories). The aims of the video will be to model uptake of the HPV vaccine, but also to reinforce self-efficacy, subjective norms, and behavioral intentions, all significant precursors to behavior change.
Study NCT02748161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DEB-TACE
Description: Transarterial chemoembolization with doxorubicin-eluting beads.
Study NCT01787708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Red light
Study NCT00654264 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Water immersion
Description: Subjects will sit in tub for four hours.
Study NCT02679053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT02679053 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Study NCT00892554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: Capsules providing 10 mg DHA/kg body weight/day taken once daily
Study NCT00892554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn/soy oil
Description: Capsules taken once daily
Study NCT01500057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Greenlight XPS Laser
Description: Treatment of BPH with Greenlight XPS laser
Study NCT03316001 — intervention group
Intervention type: OTHER
Intervention: Review of multidetector row computed tomography scans
Description: multidetector row computed tomography scans
Study NCT01973348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-hour AmblyZ glasses
Description: 4-hour AmblyZ glasses for moderate amblyopia
Study NCT01973348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-hour AmblyZ glasses
Description: 12-hour AmblyZ glasses for severe amblyopia
Study NCT01973348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-hour patching
Description: 2-hour patching for moderate amblyopia
Study NCT01973348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6-hour patching
Description: 6-hour patching for severe amblyopia
Study NCT01313949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program \[NLP\] trainer to ensure the adequacy of knowledge and skills of these mentors.
Study NCT01790204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Watercress Juice
Description: The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
Study NCT01853553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Blood pressure medication.
Study NCT01853553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Placebo.
Study NCT03982485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg, Oral, day 2,3,4,5,6,7, every week
Study NCT03982485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle
Study NCT03982485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle
Study NCT03982485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle
Study NCT01500057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiVAP Saline Vaporization of the prostate
Description: treatment of BPH with BiVAP Saline Vaporization
Study NCT03982485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle
Study NCT03982485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT03982485 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery
Study NCT02606994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Defense Toothpaste
Description: Brush with a Oral Defense Toothpaste three times per day during the study
Study NCT01037283 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal and Social Rhythm Therapy
Description: Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
Study NCT02606994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crest Toothpaste
Description: Brush with Crest Toothpaste three times per day during the study
Study NCT02606994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magic Mouth Rinse
Description: Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
Study NCT02005120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intrapleural administration of bevacizumab
Study NCT02005120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: Intrapleural administration of recombinant human endostatin
Study NCT05699720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium Sulphate
Description: Group A received 250mg of MgSO4 /dose given through nebulizer four times a day, while group B did not. The groups will be followed for five days to see the results in terms of in-hospital outcome, whether the patient is discharged after fulfilling the set criteria or needing assisted ventilation.
Study NCT00732095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Self-Change with Ads
Description: Use of Ads immediate or delayed or no ad
Study NCT02015390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous RIA bone grafting
Description: After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.
Study NCT00354601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral capecitabine twice daily on days 1-21
Study NCT02015390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic bone grafting
Description: After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).
Study NCT01213901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Description: Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
Study NCT00354601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel IV over 30 minutes on days 1, 8, and 15
Study NCT02048111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IB1001
Description: Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.~The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.~The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator.
Study NCT02291562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: 10 mg Tetrahydrocannabinol (capsule, once) oral intake
Study NCT02291562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: 600 mg Cannabidiol (capsule, once) oral intake
Study NCT02291562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (capsule, once) oral intake
Study NCT05116124 — intervention group
Intervention type: OTHER
Intervention: dosing of inflammatory parameters
Description: View and register the dosing of inflammatory parameters
Study NCT00555230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
Study NCT00555230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
Study NCT00949312 — intervention group
Intervention type: GENETIC
Intervention: RNA marker analysis of lymph node and primary tumors
Study NCT00949312 — intervention group
Intervention type: GENETIC
Intervention: microarray profiling of primary tumors
Study NCT00949312 — intervention group
Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction of lymph node specimens
Study NCT00949312 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory RNA and DNA biomarker analysis of primary tumors
Study NCT00949312 — intervention group
Intervention type: PROCEDURE
Intervention: regional lymph node dissection
Study NCT00949312 — intervention group
Intervention type: OTHER
Intervention: lymph node staining for H&E and pancytokeratin IHC
Study NCT02202486 — intervention group
Intervention type: OTHER
Intervention: Brain MRI
Description: Brain MRI with gadolinium contrast
Study NCT03354221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: Patients undergoing the six food elimination diet will be monitored during the initial elimination period at 2, 4 and 6 weeks with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
Study NCT03354221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: During the initial 6 week elimination period, participants will eliminate the 6 most common food allergens from their diet (fish, nuts, eggs, soy, wheat, dairy). Participants will return for the cytosponge during this time at 2, 4 and 6 weeks of elimination.
Study NCT03354221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEsAI Pro
Description: This is a short questionnaire to assess the participants swallowing. This will be completed at baseline and during each cytosponge visit during the initial elimination period (2, 4, 6 weeks).
Study NCT03354221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Likert Scoring Scale
Description: This is a short questionnaire for patients to compare their experiences swallowing the cytosponge versus completing an upper endoscopy. The scale is rated from worst experience to best experience.
Study NCT02898545 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SEEQ monitor
Description: An external cardiac rhythm monitor
Study NCT01959256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual perceptual learning
Description: 24 times of training for visual perceptual learning
Study NCT01958463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota transplantation.
Description: Fecal Microbiota transplantation during colonoscopy.
Study NCT04195971 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver CT
Description: Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.
Study NCT00641511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN117 (nepicastat)
Description: 120 mg per day
Study NCT00641511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: once per day placebo capsules
Study NCT01584544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study NCT02371265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence and retention package
Description: Based on formative research findings, the following core components of the B+ study intervention have been designed and will be stepped in at the study sites to improve early retention in care and adherence:~* Workflow modification: 1) Redefinition of key roles of MCH nurses and task shifting to community health workers (CHW's), and 2) enhanced patient tracking via improved management of registries/charts;~* Adherence and retention package: 1) Creation of Adherence Committees at each site to coordinate and systematize patient follow-up, 2) active patient follow-up and home visits by community health workers (CHWs or activistas), 3) use of text messaging to patients by MCH nurses, 4) improved and intensified counseling coordinated with active CHW and text follow-up, and 5) intensified and improved Option B+ training and supportive supervision.
Study NCT03931239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval
Description: An openlabel, multicentric, bridging study to assess the safety of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine (Adsorbed) manufactured by Serum Institute of India Pvt. Ltd in Vietnamese infants aged 6-12 weeks, given as a 3-dose regime, with 4 week intervals between the doses
Study NCT03563105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Ox-Imager Mini (Desaturation)
Description: Vascular Occlusion Test
Study NCT03733509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Block
Description: One shot adductor canal nerve block with 20ml of bupivacaine 0.25% through surgical incision
Study NCT03733509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Block
Description: One shot adductor canal nerve block with 20ml of bupivacaine 0.25% mid-thigh
Study NCT03733509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Placebo
Description: One shot adductor canal nerve infusion with 20ml of saline solution through surgical incision
Study NCT03733509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Placebo
Description: One shot adductor canal nerve infusion with 20ml of saline solution mid-thigh
Study NCT00440557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 3 times weekly /once weekly
Description: Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
Study NCT02542488 — intervention group
Intervention type: OTHER
Intervention: STOPBANG Questionnaire
Description: 8 question screening tool comprised of the following questions:~S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI >35 kg/m2? A: Are you >50 years old? N: Is your neck circumference >40cm? G: Is your gender male?
Study NCT02542488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Overnight pulse oximetry
Description: All participants will be given a Masimo Rad8 pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
Study NCT02542488 — intervention group
Intervention type: OTHER
Intervention: Epworth Sleepiness Scale
Description: A questionnaire that rates how tired they are doing everyday tasks
Study NCT01584544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study NCT01584544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study NCT02271165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin (Hizentra)
Study NCT02999087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
Study NCT02999087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
Study NCT02999087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab
Description: IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
Study NCT02999087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
Study NCT02999087 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
Study NCT02999087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).